Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV-F Vaccine in Healthy Women
NCT01704365Phase 2Completed
- Sponsor
- Novavax
- Start
- Oct 2012
- Primary completion
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rsv-f protein nanoparticle vaccine in respiratory syncytial virus infection (RSV), sponsored by Novavax. Started Oct 2012; status: completed.
02
Drugs
rsv-f protein nanoparticle vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT01704365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01704365.